Our range of ELISA and RIA kits includes:
Vitamin D deficiency is an important risk factor for rickets, osteomalacia, senile osteoporosis, cancer and pregnancy outcomes. The measurement of both 25OH Vitamin D forms is required to determine the cause of abnormal serum calcium concentrations in patients. Vitamin D intoxication has been shown to cause kidney and tissue damages.
Sclerostin is a regulatory marker of bone turnover. It is a 22.5 kDa secreted glycoprotein that is a potent inhibitor of Wnt signalling. It acts by binding to the Wnt-coreceptor LRP5/6 thus inhibiting bone formation by regulating osteoblast function and promoting osteoblast apoptosis.
The new Biomedica ELISA kit for Bioactive Sclerostin is now available.
Periostin is associated with epithelial-mesenchymal transition in cancer and the differentiation of mesenchyme in the developing heart. Periostin has functions in osteology, tissue repair, oncology, cardiovascular and respiratory diseases, and in various inflammatory settings.
Osteoprotegerin (OPG) or osteoclast inhibitory factor (OCIF) is a glycoprotein of the tumour necrosis factor receptor superfamily encoded by the TNFRSF11B gene. OPG is produced by many tissues and cell types including osteoblasts, breast tissue, vascular endothelial cells as well as B cells and dendritic cells in the immune system.
RANKL, the receptor activator of nuclear factor kappa B ligand, a member of the tumour necrosis factor (TNF) family, is the main stimulatory factor for the formation of mature osteoclasts and is essential for their survival. RANKL activates its specific receptor RANK, located on osteoclasts and dendritic cells.
DKK-1 is a 25.8 kDa secreted protein functioning as antagonist of the canonical Wnt signalling pathway. DKK-1 is a biomarker of cancer progression and prognosis as well as potential therapeutic target in various types of malignancies. It is associated with the formation of bone metastasis and osteolytic bone lesions.
Semaphorin 4D is involved in cell-cell communication and is widely studied for its role in neural connectivity, vascularisation, cell migration, immune responses, tumour progression, and bone remodelling.
FGF23 (fibroblast growth factor 23) is a member of the fibroblast growth factor family and controls phosphate and vitamin D homeostasis. The main source of FGF23 is osteocytes in the bone and it is present in the circulation as hormonally intact FGF23 and inactive N-terminal and C-terminal fragments.
Intact PINP is liberated into the blood stream during the formation of new bone. The concentration of PINP is directly related to the rate of bone turnover. Measuring the level of PINP is helpful in the identification of patients at high risk of fracture, and in monitoring the effectiveness of osteoporosis treatment. It is a dynamic marker showing the rate of bone turnover.
Carboxyterminal cross-linked telopeptide of type I collagen is a crosslinked product of collagen degradation and is released from bone when it is being degraded under pathological conditions. It is measured to help in the early detection of skeletal bone metastases in breast, lung, and prostate cancers, and for the detection of minor changes in bone turnover much earlier than seen in a bone scan.
Intact PIIINP is liberated into the circulation during soft tissue formation. Measuring serum levels of PIIINP is useful in monitoring fibrosis, monitoring methotrexate treated psoriatics, and can be used as a prognostic marker in cardiac failure.
Osteocalcin is synthesised in the bone by osteoblasts and is the major non-collagen protein of the bone matrix. Measurement of osteocalcin in the circulation can aid in monitoring bone metabolism.
α KLOTHO is expressed in kidney, small intestine, placenta and prostate and the soluble peptide can be found in serum and cerebrospinal fluid. It may play a role in the calcium/ phosphorus homeostasis regulation by e.g. inhibiting active vitamin D synthesis, and is known as an anti-aging hormone by extending life span by inhibiting the insulin/ IGF1 signalling pathway. KLOTHO is a co receptor of fibroblast growth factor 23 (FGF 23) and is of interest in the investigation of chronic kidney disease and failure, renal and hepatocellular carcinomas, osteoporosis and cardiovascular diseases.
Please visit our Downloads page for specific brochures or contact us directly to discuss your specific assay requirements.